Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species

@article{Shen2016CoproporphyrinsIA,
  title={Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species},
  author={Hong Shen and Jun Dai and Tongtong Liu and Yaofeng Cheng and Weiqi Chen and C. Freeden and Yingru Zhang and W. Humphreys and P. Marathe and Y. Lai},
  journal={The Journal of Pharmacology and Experimental Therapeutics},
  year={2016},
  volume={357},
  pages={382 - 393}
}
  • Hong Shen, Jun Dai, +7 authors Y. Lai
  • Published 2016
  • Biology, Medicine
  • The Journal of Pharmacology and Experimental Therapeutics
Inhibition of organic anion-transporting polypeptide (OATP)1B function can lead to serious clinical drug-drug interactions, thus a thorough evaluation of the potential for this type of interaction must be completed during drug development. Therefore, sensitive and specific biomarkers for OATP function that could be used in conjunction with clinical studies are currently in demand. In the present study, preclinical evaluations were conducted to characterize the suitability of coproporphyrins… Expand

Paper Mentions

Observational Clinical Trial
This is a single center, comparative cohort study to investigate alterations in hepatic transporter function in subjects with autosomal dominant polycystic kidney disease (ADPKD… Expand
ConditionsADPKD, Autosomal Dominant Polycystic Kidney Disease, Renal Disease
In Vitro–In Vivo Extrapolation of OATP1B-Mediated Drug–Drug Interactions in Cynomolgus Monkey
Hepatic organic anion-transporting polypeptides (OATP) 1B1 and 1B3 are clinically relevant transporters associated with significant drug–drug interactions (DDIs) and safety concerns. Given thatExpand
Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition
TLDR
It is concluded that CP-I and CP-III in plasma and urine can be appropriate endogenous biomarkers specifically and reliably reflecting OATP inhibition, and thus the measurement of these molecules can serve as a useful tool to assess OatP drug-drug interaction liabilities in early clinical studies. Expand
Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I
TLDR
Systematic evaluation of plasma data obtained for 20 endogenous molecules in the same healthy subjects in the absence and presence of organic anion transporting polypeptide (OATP) inhibitor rifampicin confirms that none of the biomarkers supersede CPI in the evaluation of OATP1B-mediated DDI risk. Expand
Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug–Drug Interactions
TLDR
The results demonstrate the selectivity of CPI and CPIII towards the OATP1B/MRP pathway, and the herein reported data further underline the potential of CPIand CPIII as selective and sensitive clinical biomarkers to quantify OATp1B-mediated DDIs. Expand
Absence of OATP1B (Organic Anion–Transporting Polypeptide) Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression
TLDR
Combined endogenous biomarker and gene expression data suggested that RIF did not induce OATP1B in cynomolgus monkeys, and this study provides evidence to strengthen the claim that coproporphyrin is a suitable endogenous probe of OATp1B activity. Expand
Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition
TLDR
Findings provide further evidence supporting the translational value of CPI and CPIII as suitable endogenous clinical probes to gauge OATP1B activity and potential for OATp1B-mediated DDIs. Expand
PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3
TLDR
A physiologically based pharmacokinetic (PBPK) model for coproporphyrin I (CP‐I), a biomarker supporting the prediction of drug‐drug interactions (DDIs) involving hepatic organic anion transporting polypeptide 1B (OATP1B), was established and the blood concentration‐time profiles of four statins were well‐predicted. Expand
Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition
TLDR
It is suggested that hepatic OATP considerably affects the disposition of CPI in animal models, indicating CPI is a sensitive and selective endogenous biomarker of OatP inhibition. Expand
Endogenous Coproporphyrin I and III Are Altered in Multidrug Resistance-Associated Protein 2-Deficient (TR-) Rats.
TLDR
The disposition of CPs was markedly altered by loss of Mrp2 and increased Mrp3 function as measured in TR- rats, which indicated that CPs are substrates of rodent Oatp1b2, and that CP-III is a substrate of O atp2b1. Expand
Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects
TLDR
Investigation of bile acids and fatty acid dicarboxylates in plasma as endogenous probes for OATP inhibition and compared these candidate probes to CPs confirmed that CPs are novel biomarkers suitable for clinical use. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 72 REFERENCES
Cynomolgus Monkey as a Potential Model to Assess Drug Interactions Involving Hepatic Organic Anion Transporting Polypeptides: In Vitro, In Vivo, and In Vitro-to-In Vivo Extrapolation
TLDR
The cynomolgus monkey has the potential to serve as a useful model for the assessment of OATP-mediated DDIs in a nonclinical setting and a number of in vitro–in vivo extrapolation approaches were explored. Expand
Pitavastatin as an In Vivo Probe for Studying Hepatic Organic Anion Transporting Polypeptide-Mediated Drug–Drug Interactions in Cynomolgus Monkeys
TLDR
Pharmacokinetic studies using pitavastatin as an in vivo probe substrate for preclinically studying OATP-mediated DDIs using cynomolgus monkeys are useful to support the assessment of potential clinical DDIs involving hepatic uptake transporters. Expand
Structure-Based Identification of OATP1B1/3 Inhibitors
TLDR
A proteochemometrics-based in silico model was developed, which predicted OATP1B inhibitors in the test group with high specificity (86%) and sensitivity (78%) and was prospectively verified with a set of 54 compounds not included in the original dataset. Expand
Dehydroepiandrosterone sulfate, a useful endogenous probe for evaluation of drug-drug interaction on hepatic organic anion transporting polypeptide (OATP) in cynomolgus monkeys.
TLDR
DHEAS may be used as endogenous probe for predicting OATP-mediated DDI for the first time, and changes in DHEAS concentration are expected to be more prominent in human than in monkey, based on the results of in vitro hepatic DHEas uptake. Expand
Evaluation of Cynomolgus Monkeys for the Identification of Endogenous Biomarkers for Hepatic Transporter Inhibition and as a Translatable Model to Predict Pharmacokinetic Interactions with Statins in Humans
TLDR
Whether cynomolgus monkeys are a suitable translational model to study OATP1B-mediated DDIs is evaluated and the inhibitory effect of RIF is determined on in vitro transport and pharmacokinetics of rosuvastatin (RSV) and atorvASTatin (ATV). Expand
Evaluation of Rosuvastatin as an Organic Anion Transporting Polypeptide (OATP) Probe Substrate: In Vitro Transport and In Vivo Disposition in Cynomolgus Monkeys
TLDR
The high levels of unchanged RSV recovered in urine and bile and the relatively low levels of metabolites observed indicated that RSV was eliminated largely by excretion, and further support the use of the cynomolgus monkey as a model to assess interactions involving OATP inhibition. Expand
Investigation of the Impact of Substrate Selection on In Vitro Organic Anion Transporting Polypeptide 1B1 Inhibition Profiles for the Prediction of Drug-Drug Interactions
TLDR
OATP1B1 substrate drugs except for torasemide and nateglinide, or E2G as a surrogate, is recommended as an in vitro probe in the inhibition experiments, which will help mitigate the risk of false-negative DDI predictions potentially caused by substrate-dependent Ki variation. Expand
Substrate-Dependent Inhibition of Organic Anion Transporting Polypeptide 1B1: Comparative Analysis with Prototypical Probe Substrates Estradiol-17β-Glucuronide, Estrone-3-Sulfate, and Sulfobromophthalein
TLDR
Substrate-dependent inhibition of OATP1B1 was shown and it was demonstrated that E2G was the most sensitive in vitro OatP1 B1 probe substrate among three substrates tested. Expand
Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.
TLDR
It is indicated that pitavastatin is a more sensitive and selective and thus preferred clinical OATP1B probe substrate than rosuvastatin, and that a single IV dose of rifampicin is aMore selective OATp1B inhibitor than a PO dose. Expand
Potential role of organic anion transporting polypeptide 1B1 (OATP1B1) in the selective hepatic uptake of hematoporphyrin monomethyl ether isomers
TLDR
OATP1B1 is the major transporter involved in the rapid hepatic uptake of HMME, and the greater uptake ofHMME-2 by OATP2B1 may lead to a lower exposure of HMme-2 than HMME-1 in humans. Expand
...
1
2
3
4
5
...